Paradromics Connexus BCI Restores Real-Time Speech in First Patient

A Michigan woman in her 60s, severely affected by a progressive motor neuron disease, used Paradromics' Connexus brain-computer interface to form her own responses and answer open-ended questions in real time — the first demonstrated case of the system restoring conversational speech. The company presented the result in September 2026, roughly three months after implanting the device in June.

The participant is the first enrollee in Paradromics' 10-person feasibility study. Using the BCI, she communicated with family members and spoke with her grandchildren over the phone. "Okay, I have a lot to say," she said in one exchange relayed by the company.

What the implant actually is

Connexus is an intracortical array — not scalp EEG, not ECoG — carrying 421 microelectrodes, each thinner than a human hair and 1.5 mm deep. The density minimizes tissue impact while capturing single-neuron resolution. The array sits on the cortical surface and floats with the brain's natural movement, avoiding the mechanical stresses that arise when an implant is fixed to the unmoving skull.

The electrodes are solid platinum-iridium, the same alloy used in stereoelectroencephalography (SEEG) electrodes and deep brain stimulation implants for Parkinson's disease and tremor. Paradromics Chief Clinical Officer Dr. Bill Marks, a neurologist, emphasized that the material choice was deliberate: the biocompatible, corrosion-resistant alloy has a documented record of remaining in tissue and functioning for years.

The entire metal-and-ceramic device is hermetically sealed, a packaging strategy borrowed from cardiac pacemakers. The system is fully wireless and housed entirely within the body, eliminating the infection risk associated with percutaneous connectors — a design constraint that matters for any monitoring-unit or infection-control conversation around chronically implanted neurotechnology.

Surgical approach and durability targets

Marks described the implantation as conventional by neurosurgical standards: simple incisions, a small craniotomy, insertion of the module under visual inspection guided by imaging, then tunneling the wire to the chest region where the internal transceiver resides.

"With tried-and-true materials and tried-and-true surgical procedures, you don't need to be highly trained or have a $5 million robot to do the procedure," Marks said in a Medical Design & Outsourcing interview. The comment signals Paradromics' positioning against robotic-insertion approaches in the BCI field.

Durability ranks as high as safety and performance in the company's engineering priorities. Paradromics targets a device lifetime of at least 10 years. In preclinical animal models, the implant has recorded from a healthy sheep's brain for more than four years with "practically no degradation in signal-to-noise ratio" and no tissue migration, according to the company. That is animal data — the human durability record is only now accumulating, starting with the June 2026 implant.

Regulatory status and scaling strategy

Connexus remains an investigational device. It carries no FDA clearance or approval; the current evidence base consists of one human participant in an early feasibility study plus preclinical animal data. In summer 2026, the FDA granted Paradromics permission to expand the types of computing devices the system can connect to — including consumer laptops, tablets and phones — as part of evaluating the BCI's everyday utility.

"Our goal is to help millions of people, not just a handful of people," Marks said. "We've deliberately built and engineered our system for scaling." The consumer-device expansion and the reliance on standard surgical techniques both serve that goal: a system that requires exotic equipment or bespoke computing hardware cannot scale to a large patient population.

For clinical neurophysiology teams, the design choices have practical reading-room relevance. Single-neuron resolution from a 421-channel intracortical array is a different signal regime from the macroelectrode recordings familiar from SEEG or ECoG work, and the speech-decoding pipeline that converts that activity into real-time output will be the subject of closer scrutiny as the feasibility study adds participants.

What comes next

Paradromics will continue enrolling patients in the early feasibility study before moving into pivotal testing. Clinical sites include the University of Michigan, Massachusetts General Hospital and the University of California, Davis. The September 2026 demonstration, FDA's permission to test consumer-device connectivity, and the planned pivotal trials together define the near-term path for whether Connexus can move from a single compelling case to evidence robust enough to support approval.